May 24, 2017 11:58 PM ET


Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.

175 Portland Street

4th Floor

Boston, MA 02114

United States

Founded in 2005

32 Employees



Key Executives for Zafgen, Inc.

Chief Executive Officer, President and Director
Age: 56
Total Annual Compensation: $463.5K
Chief Financial Officer
Age: 54
Total Annual Compensation: $320.0K
Chief Medical Officer
Age: 46
Total Annual Compensation: $378.5K
Compensation as of Fiscal Year 2016.

Zafgen, Inc. Key Developments

Zafgen, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017

Zafgen, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $13,265,000 compared to $17,857,000 a year ago. Net loss was $13,011,000 or $0.48 per basic and diluted share compared to $17,736,000 or $0.65 per basic and diluted share a year ago. Interest income was $227,000 compared to $209,000 a year ago.

Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061

Zafgen, Inc. announced positive topline data from its Phase 1 clinical trial of ZGN-1061, the Company second generation MetAP2 inhibitor. ZGN-1061 demonstrated rapid drug absorption and clearance in line with pre-specified criteria established for the molecule, and was well-tolerated and safe, with no evidence of prothrombotic effects. Patients in the clinical trial experienced mean weight loss of up to approximately one pound per week. The Phase 1 clinical trial included a single ascending dose (SAD) phase, which enrolled healthy volunteers, and a multiple ascending dose (MAD) phase, which evaluated twice-weekly administration of ZGN-1061 in overweight or obese patients over four weeks. The SAD phase was comprised of six dosing cohorts ranging from 0.2 mg to 4.8 mg and the MAD phase was comprised of three dosing cohorts of 0.2 mg, 0.6 mg and 1.8 mg. The SAD phase included 39 volunteers (ZGN-1061 N=28, placebo N=11), 90% male and average body mass index (BMI) of 26 kg/m2; and the MAD phase included 29 patients (ZGN-1061 N=22, placebo N=7), 76% male and average BMI of 33 kg/m2. Patients in the MAD phase were domiciled while receiving treatment and were subjected to inpatient safety monitoring for most of the clinical trial 28-day duration.

Zafgen, Inc. - Special Call

To discuss the Phase 1 clinical trial data and provide a financial update

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zafgen, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at